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of molecular biology has identified several key events that 
contribute to the molecular pathogenesis of skin cancers 
including basal cell carcinomas (BCCs), squamous cell 
carcinomas (SCCs), and others. Interestingly, there are a 
number of new therapeutic strategies that are able to spe-
cifically target the affected pathways.
 Smoothened-Targeted Therapy in BCC 
 Molecular Biology of BCC 
 BCC is one of the most common neoplasms in the 
Caucasian population. Molecular events that are seen in 
these tumors are rather monotypic in comparison to oth-
er malignancies, with translocations and inversions in-
volving 9q being a common aberration in BCCs  [1–3] . 
BCCs rarely develop metastases and are considered to be 
genetically stable. The high level of stability associated 
with BCC has been confirmed using comparative genom-
ic hybridization  [4] and loss of heterozygosity  [5] analyses 
which showed a reoccurrence of loss on 9q (in 30–60% of 
tumors), further refining this region as 9q22. Other aber-
rant loci present in more then 10% of the cases and de-
tected in these and similar studies using molecular-based 
cytogenetic approaches included chromosome arms 1q, 
6p, 6q, 9p, 17p, 17q, and chromosome X  [4, 6–9] .
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 Abstract 
 Today skin cancer is mainly treated by surgical interventions. 
New findings concerning molecular biology and the signal-
ing pathways in epithelial skin cancers such as basal cell 
 carcinoma, squamous cell carcinoma or melanoma, and 
mesenchymal skin cancers such as angiosarcoma and der-
matofibrosarcoma protuberans (DFSP) have identified new 
molecular targets for a systemic or local treatment approach. 
For DFSP there is an opportunity already today to reduce the 
intensity of surgical procedures by pretreatment with tar-
geted therapy. This article highlights important aspects in 
several skin cancer types.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Skin cancer is more common than all other cancer 
forms in human beings. Virtually every single cell type 
in the skin can transform and start uncontrolled prolif-
eration. In the last decades, intensive research in the field 
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 The majority of BCCs are sporadic, but there is a con-
genital syndrome, i.e. basal cell nevus syndrome (BCNS), 
which promotes tumor onset. The main promotion of 
the development of BCCs is provided by sun exposure; 
however, this relation is complex. Extensive work was 
done to find predisposing epidemiological factors to ex-
plain this tight relation between the environment and 
BCC development. Among the contributing polymor-
phic alleles known to date one can name cytochrome 
P-450 (CYP2D6 EM genotype), glutathione S-transfer-
ase-null genotypes (GSTT1 and GSTM1), GSTM3, vita-
min D receptor, and tumor necrosis factor gene poly-
morphisms  [10–18] . Very recent association studies of 
Eastern European and Icelandic cohorts of BCC patients 
detected fair skin haplotypes of ASIP and TYR loci to 
increase the risk of BCC development as well as single 
nucleotide polymorphism variants on 1p36 and 1q42 
loci. These new discoveries can point to new targets for 
BCC chemotherapy  [19, 20] .
 Somatic mutations were found in several genes in-
volved in the Hedgehog (HH) signaling pathway. The 
first described were mutations in patients with BCNS 
found in the patched homologue 1  (PTCH1) gene located 
on chromosome 9q22  [21–24] . BCNS was described by 
Robert Gorlin in the middle of the last century and is of-
ten presented as the development of multiple (tens to hun-
dreds) BCCs in an affected patient and at a young age  [25] . 
Patients with BCNS also have a higher risk of developing 
other types of malignancies, especially medulloblasto-
mas (MB) and radiotherapy-induced BCCs  [6–8] . PTCH1 
is a human homolog of the patched (ptc) gene in  Dro-
sophila melanogaster and functions as an inhibitor of the 
HH signaling pathway. Mutations in this gene lead to 
constant upregulation of the pathway which is crucial in 
the development of all BCCs  [26, 27] . PTCH1 is not the 
only gene in the mutation spectrum of BCC which in-
cludes genes that regulate skin color, members of the 
phosphoinositide 3-kinase (PI3K)-Akt and the Wnt path-
ways, FOXM1 and DNA damage repair genes, and TP53 
 [28–30] . Furthermore, about 10% of tumors carry muta-
tions in the gene smoothened (SMO), another important 
member of the HH pathway encoding a regulator down-
stream of PTCH1  [31–34] .
 Definition of the above-mentioned events in the mo-
lecular pathogenesis of BCC has led to the well-accept-
ed conclusion that upregulation of the HH signaling 
pathway is essential to promote BCC initiation. There-
fore, this signaling pathway has been chosen as a privi-
leged target for the development of molecular interven-
tions.
 HH Pathway 
 Elucidation of molecular aberrations in BCCs enabled 
the subsequent characterization of a group of human 
cancers where disturbances of the HH signaling pathway 
govern tumor development.
 In brief, a family of extracellular ligands with 3 
 members, i.e. Sonic Hedgehog (SHH), Desert Hedgehog 
(DHH), and Indian Hedgehog (IHH), initiates the HH 
signaling cascade. All 3 protein ligands are able to bind 
Patched 1 (PTCH1), a 12-pass transmembrane receptor 
protein which releases its repression of the pathway activ-
ity upon binding of a ligand. PTCH1 suppresses the HH 
signaling pathway through the inhibition of the G pro-
tein-coupled receptor-like protein Smoothened (Smo), 
which serves as a pathway activator. Through a range of 
protein interactions Smo transmits a signal to the genes 
amplified in glioblastoma (Gli) family of transcription 
factors. When the signal reaches the Gli transcription 
factors, Gli1, Gli2, and/or Gli3, changes in transcription 
can then lead to cell proliferation and differentiation  [35, 
36] . Interestingly, stem cells express a lot of genes that are 
transcriptionally regulated by Gli 1, 2, and/or 3, thus pro-
viding a link between the HH signaling pathway and 
stem cell function. A short list of target genes involves 
Gli1, PTCH1, D-type cyclins, BMI1, and Bcl2. Included 
amongst the transcriptional targets of HH signaling in 
BCCs are the pathway’s own members:  PTCH1 , forming 
a negative feedback that dampens the pathway;  GLI1 , pro-
viding a positive feedback for the pathway, and  HHIP , 
which encodes an HH-binding protein  [37, 38] .
 The HH pathway activity is important for the develop-
ment and homeostasis of several organs and tissues  [39] . 
The physiological mechanism of HH signaling is para-
crine; however, during carcinogenesis it is suggested that 
an autocrine mechanism may be involved  [40] . The de-
velopment of several tumor types is stimulated by muta-
tions in PTCH1 or downstream Smo proteins. Thus, 
germ line mutations in PTCH1, within manifestations of 
BCNS, lead to the development of medulloblastoma, 
ovarian cysts, and ovarian carcinoma. In terms of inci-
dence, mutations in Ptch and/or Smo genes leading to 
activation of the HH pathway are found in more than 
70% of sporadic BCC  [32, 41] and in 20–30% of MB  [42, 
43] .
 Smoothened-Targeted Compounds 
 Elaboration of small molecule antagonists of Smo was 
encouraged by the elucidated and clear molecular path-
way of tumor development in BCCs. Since the most prev-
alent mutations in BCC are activating mutations in 
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PTCH1 and SMO genes, HH signaling becomes ligand 
independent in these tumors. Thus, blockade of ligand 
binding will not result in a therapeutic effect, and inhibi-
tion must be targeted to Smo and downstream signaling 
molecules.
 The first Smo-targeted inhibitors, i.e. cyclopamine 
and jervine, were isolated from corn lilies  (Veratrum cal-
ifornicum) as teratogenic and antitumor agents  [44–46] . 
However, the chemical structure of these plant alkaloids 
resulted in low-affinity binding to the Smo protein and 
decreased bioavailability. This fostered the development 
of new potent synthetic modifications such as HhAntag 
 [47] , SANT1-SANT4  [46, 48] , Cur-61414  [49] , GDC-0449 
 [50] , and very recently IPI-926  [51] . Several of these in-
hibitors were able to prevent in vivo tumor progression in 
MB models driven by mutations in Ptch  [52, 53] . GDC-
0449 is a new-generation, orally administrated, synthetic 
Smo inhibitor possessing higher potency and specificity. 
In a recent phase I trial, systemic administration of GDC-
0449 showed promising tumor regressions in metastatic 
or locally advanced BCC  [54] . With respect to clinical 
testing, very few Smo inhibitors have been used to date in 
humans. The pioneer is cyclopamine, which is reported 
to induce the regression of sporadic human BCCs after 
topical application and inhibit the xenograft growth of 
HH-overexpressing tumors  [40, 55–59] . Another mole-
cule tested topically in humans is Cur-61414, but this 
promising synthetic Smo agonist did not penetrate
human skin well (http://www.curis.com/news.php). The 
problem of skin penetration is a recurrent obstacle for 
topical drug application. Presently several strategies are 
being pursued in order to overcome this issue. One of the 
actively explored possibilities for cancer therapy is the use 
of nanoparticles to deliver drugs under the stratum cor-
neum. Some advances have been made recently with the 
development of solid lipid nanoparticles and core-multi-
shell nanoparticles which can penetrate the skin with 
high efficiency  [60–62] . More promising results, as has 
already been mentioned, have been obtained using sys-
temically administrated GDC-0449. This molecule, as 
well as IPI-926, is now entering further clinical trials, is 
well tolerated, and has very limited acute and chronic 
toxicity  [63] .
 The current active development of therapeutic agents 
targeting Smo opens several promising therapeutic ave-
nues. Most promising for the treatment of restricted areas 
is topical application, as has been shown for cyclopamine, 
thus avoiding systemic exposure. Points for consider-
ation in this respect are: (1) the long-term complete clear-
ance rate, (2) the types of BCCs responding to treatment 
(superficial BCC vs. nodular BCC vs. aggressive infiltra-
tive BCC), (3) the time period required to reach tumor 
clearance, and (4) local side effects and the cosmetic out-
come. Patients with a genetically determined high inci-
dence of BCC, e.g. xeroderma pigmentosum or BCNS pa-
tients, can profit from systemic therapy. New molecules 
might be investigated in these patient populations as 
monotherapeutic tools and in the context of chemopre-
vention. If successful, such new Smo-targeting drugs 
could then be investigated in patients with multiple spo-
radic BCCs. Mounting evidence from mouse models of 
BCC, as well as early experiences with local and systemic 
utilization of SMO antagonists, indicates that molecular 
interventions inhibiting the HH signaling pathway are 
promising approaches for the treatment of BCC. It is also 
important to note that there is no evidence that mutation 
screening is needed before enrolling patients for such a 
treatment because the vast majority of mutations found 
in BCCs are mutations leading to HH pathway activation 
in a ligand-independent manner. These include inacti-
vating PTCH1 mutations leading to the lack of pathway 
repression (approximately 90% of mutations) and activat-
ing SMO mutations leading to constant further signaling 
(  10% of mutations); mutations in the HH ligand itself 
are also described  [33, 34, 63–66] . However, mutations 
occurring during treatment may be a concern. As it has 
been reported for MB, GDC-0449 appears to be able to 
induce tumor mutagenesis leading to chemoresistance. 
Therefore, combination therapy will be investigated with 
agents interfering with molecules downstream of the HH 
pathway, such as TGF-  , MAPK, or PI3K inhibitors  [67–
70] .
 The great need for well-tolerated local and systemic 
treatment options in patients with multiple BCCs is ex-
plained by the continuously increasing incidence of these 
tumors. It is still unclear which mode of administration, 
systemic or local, will yield the best efficacy-to-risk ratio. 
This parameter will determine the place for Smo-target-
ed therapy in a competitive environment of BCC treat-
ment options alongside surgical procedures, physical 
therapy (irradiation or photodynamic therapy), and topi-
cal immune modulation.
 Currently Used Drug Therapy for BCC 
 There are currently several options available for the 
treatment of BCCs, e.g. 5-fluorouracil (5-FU), a pyrimi-
dine-like inhibitor of thymidylate synthase which pre-
vents DNA synthesis in tumor cells. The exact mecha-
nism of action in BCC remains unclear for this drug, but 
it has been suggested that 5-FU downregulates HH path-
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way target molecules at both the messenger RNA and 
protein levels. Interestingly, upregulation of the Gli1 
transcription factor restores cell viability and migration 
inhibited by 5-FU  [71] .
 Based on our improved understanding of the molecu-
lar genetics of BCCs, retinoids, especially tazarotene 
(Tazorac; Allergan), are promising tools for prevention or 
therapy. Tazarotene has been shown to decrease Gli1 ex-
pression and upregulate CRABPII, a target gene of reti-
noid signaling. Retinoids act through the transcription 
factors RAR and RXR initiating cellular differentiation 
and apoptosis as well as extracellular matrix synthesis. 
They are widely used to treat inflammatory (such as pso-
riasis or chronic eczema) or neoplastic diseases including 
acute promyelocytic leukemia, cutaneous T-cell lympho-
mas, and non-melanoma skin cancers. In Ptch1+/– mice 
a controlled chemoprevention trial demonstrated that 
the topical use of tazarotene inhibits the formation of 
BCCs induced with either UV or ionizing radiation  [72, 
73] . The total complete clearance rate for BCCs was, how-
ever, only 30.5%; therefore, topical tazarotene is not a re-
liable therapeutic option. In contrast, the substance might 
be useful as a chemopreventive topical approach based on 
the data derived from animal models. Prospective trials 
in humans are testing this hypothesis.
 A potent therapeutic agent for the treatment of selected 
BCCs is imiquimod, a low-molecular-weight synthetic 
immunomodulator which can induce up to 87% of the 
clinical and histologically verified clearance of superficial 
BCCs. One of the major antitumor actions of imiquimod 
is the induction of inflammation resulting in an IFN-  -
driven immune response which has also been confirmed 
in a mouse model of melanoma  [74] . Molecularly this is 
achieved through triggering of the Toll-like receptor 7/
MyD88/NF-  B pathway and the consequent induction, 
synthesis, and release of selected cytokines, including 
IFN-  by plasmacytoid dendritic cells. This ability of im-
iquimod mimics a well-documented treatment of BCC 
with repeated intratumoral injections of IFN-   [75] . Si-
multaneously, imiquimod promotes the migration and 
activation skin Langerhans cells to the regional lymph 
nodes, Bcl-2-dependant apoptosis of tumor cells and sup-
presses feedback mechanisms limiting inflammatory re-
sponses  [76] . How much these pathways contribute to tu-
mor repression in vivo is still undefined  [77, 78] . Another 
interesting phenomenon is the preferential upregulation 
of Jagged1 protein after treatment with imiquimod. Jag-
ged1 plays an important role in the differentiation of ke-
ratinocytes as activation of the Notch pathway triggers 
terminal keratinocytes differentiation  [79] .
 Epidermal Growth Factor Receptor-Targeted 
Therapy in SCC 
 SCC is another very common type of cutaneous ma-
lignancy and the second most common cancer in the Eu-
ropean population. The increase in its incidence, along 
with the incidence of BCC, is also attributed to the extent 
of UV irradiation acquired during a personal lifespan 
 [80, 81] . Quite often advanced-stage SCCs occur in el-
derly patients and the use of systemic chemotherapeutic 
agents in such cases represents a certain clinical problem. 
Therefore, the development of safe and specific molecu-
lar-targeted therapies is also of great importance here. A 
good candidate for such development is epidermal growth 
factor receptor (EGFR), which is considered to be widely 
expressed on the surface of SCC cells. Immunohisto-
chemical evaluations of EGFR expression revealed posi-
tivity for 40–100% of SCC tumor samples  [82–84] . Since 
phosphorylation of EGFR is associated with the activa-
tion of downstream signaling, evaluation of the phos-
phorylated form of EGFR was performed by Fogarty et al. 
 [85] and the rate was 25%.
 EGFR is an important regulator of tumor progression 
and proliferation in several types of cancer. Preclinical 
and clinical tests are now focused on 2 types of EGFR-
inhibiting strategies: (1) anti-EGFR monoclonal antibod-
ies that block its interaction with endogenous ligands (e.g. 
EGF and TGF-  ) and (2) small-molecule tyrosine kinase 
inhibitors that inactivate EGFR. Using either approach 
enables the discontinuation of signal transduction down-
stream of the EGFR and results in the arrest of tumor 
proliferation and spread  [86–88] . Several drugs, which 
are products of both development strategies, have been 
clinically tested in recent years. Examples are: cetuximab, 
panitumumab, erlotinib, and gefitinib. Cetuximab yield-
ed quite promising results in a phase II multicenter study 
evaluating its potential as a first-line monotherapy for pa-
tients with unresectable SCC. These results were present-
ed at the annual ASCO meeting in 2008 and showed that 
77% of patients had stable disease under cetuximab ther-
apy and 22% of patients had a partial response  [89] .
 Despite the promising response rates among non-
small cell lung cancer patients who carry somatic muta-
tions in EGFR (the incidence is about 10–15% of the Cau-
casian population and 30–40% of the Asian patient pop-
ulation), medical problems persist since a large number 
of patients develop resistance to EGFR inhibitors  [90] . In 
this respect, description of a signaling crossover between 
HH and EGF pathways in brain, prostate, and skin cell 
models opens new horizons for therapeutic strategies. 
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JUN is primarily a transcription activator and its func-
tion can be regulated at different levels and depends on 
phosphorylation by JNK, a target of the MAPK pathway 
[reviewed in  91 ]. A suggested mechanism of HH-EGF 
pathway interaction is through the EGFR-mediated acti-
vation of MEK/ERK and JUN cascades and subsequent 
stimulation of JUN/AP-1 binding with promoters of GLI 
and ERF target genes, which lead to cancer transforma-
tion and invasive growth  [92–96] . An interesting recent 
publication reported the successful use of cetuximab and 
the COX-2 inhibitor celecoxib in an elderly patient  [81] . 
Such a complex interaction of various molecular path-
ways provides further opportunities for the development 
of combination therapies of SCC treatment using a com-
plete range of known drugs, including MEK/RAF/RAS 
inhibitors, among others.
 Somatic mutations in EGFR are reported in about 10% 
of non-small cell lung cancer cases. Data about the muta-
tion rates in SCC are missing; however, knowledge of the 
mutation status in SCC patients may be important for re-
sponse prediction, e.g. in relation to deletion in exon 19. 
At present, no additional molecular knowledge is needed 
to start anti-EGFR therapy in SCC as opposed to lung can-
cer  [97] . Nevertheless, it should be noted that SCC histol-
ogy is associated with a better response to anti-EGFR ther-
apy in esophageal cancer  [98] . A more significant issue is 
acquired chemoresistance to EGFR inhibitors which can 
occur through mutations in EGFR, KRAS, and NRAS or 
through MET amplification, which leads to RAF/MAPK/
ERK or PI3K/AKT pathway activations  [97, 98] . This phe-
nomenon raises a question regarding the better perfor-
mance of multikinase inhibitors versus immunothera-
peutic agents but, unfortunately, clinical data to be able to 
privilege one class over the other are lacking at present.
 Targeted Therapy in Melanoma 
 Melanoma is a highly aggressive malignancy originat-
ing from melanocytes. Most commonly melanoma occurs 
on the skin, and its incidence rate is constantly increasing 
worldwide. Presently, it is estimated that around 20 out of 
100,000 persons per year will develop a melanoma and 
 estimated lifetime risk for this diagnosis, e.g. in Central 
Europe, is as high as 1: 70  [99] . The majority of affected pa-
tients are between the ages of 50 and 60 years, but one fifth 
of patients are under the age of 40. Active research recent-
ly revealed a number of common genetic aberrations in 
melanoma; these include BRAF and RAS mutations caus-
ing activation of the MEK-kinase signaling pathway as 
well as deletions and amplifications in the genome  [99, 
100] . However, to date, the therapeutic arsenal lacks effi-
cient treatment modalities that can prolong overall sur-
vival rates in patients with metastatic (stage IV) melano-
ma, and there has been no significant change in the mor-
tality rate associated with melanoma over the past years.
 Finding effective therapeutic options to treat melano-
ma has been an ongoing challenge over the past several 
decades. Because melanocytes originate from highly mo-
tile cells, they are thought to have a high potential for en-
hanced survival. In vivo, melanoma cells show low levels 
of spontaneous apoptosis, and in vitro resistance occurs 
against drug-induced apoptosis  [101] . Regarding thera-
peutic options, a distinction between melanoma subtypes 
according to their genetics and biological behavior must 
be made  [102–107] . For instance, superficial spreading 
melanomas, which usually occur on areas of the skin that 
are not regularly exposed to UV light, are prone to muta-
tions in the BRAF molecule which leads to the activation 
of signal transduction via RAS and MEK/MAP/ERK-ki-
nase pathways  [107] . Bastian et al.  [102, 103] recently de-
tected a distinct pattern of chromosomal aberration spe-
cific to acrolentiginous as well as mucosal melanomas, 
thus emphasizing the importance of distinguishing dif-
ferent melanoma types, especially in the context of the 
increasing number of investigative or registered targeted 
treatment options currently available. Acrolentiginous 
melanoma is a rare entity accounting for 2–3% of mela-
noma  [108] ; mucosal melanoma only accounts for 0.03% 
of all melanoma types  [109] . Such genetic heterogeneity 
underlines the necessity of performing genetic evalua-
tions of melanoma patients (i.e. for the presence of the 
BRAF or RAS mutation) in order to choose the correct 
chemotherapeutic and/or targeted agent for each sub-
group and poses the new challenge of personalized treat-
ment protocols.
 RAS/RAF Inhibitors 
 BRAF mutations are present in over 60% of melanoma 
biopsies. About 90% of BRAF mutations in melanoma 
reveal a substitution of valine to glutamic acid at position 
600, the V600E mutation  [110] . Another 15–30% of mela-
noma samples carry mutations in NRAS, most common-
ly induced by a leucine-to-glutamine substitution at posi-
tion 61  [111] .
 BRAF and NRAS mutations are mutually exclusive, 
and consequently 75–90% of melanomas carry activating 
mutations in the Ras/Raf/MEK/ERK MAPK pathway. At 
the end of this pathway, ERK is phosphorylated and acti-
vates transcription factors implicated in tumor develop-
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ment. Furthermore, V600E BRAF stimulates vascular 
 endothelial growth factor (VEGF) secretion, promoting 
angiogenesis  [112, 113] . NRAS also activates the PI3K 
pathway, leading to proliferation and invasion  [114] . Al-
though mutated BRAF and NRAS are also frequently 
found in benign nevi, nevi lack other specific gene altera-
tions, thus preventing malignant transformation  [115–
118] . BRAF mutations in benign nevi are supposed to be 
associated with induction of senescence  [119] . Thus, mel-
anoma is a good indication for the development of drugs 
targeting the MAPK. Several MAPK kinase inhibitors 
have recently been developed and these are classified as 
either BRAF inhibitors or MEK inhibitors as described 
below.
 RAF Inhibitors 
 The multikinase inhibitor sorafenib (Nexavar  , BAY 
43-9006; Bayer AG, Leverkusen, Germany) targets RAF, 
VEGF receptors (VEGFR) 1, 2, and 3, as well as platelet-
derived growth factor (PDGF)-  and PDGF-  , resulting 
in inhibition of tumor cell proliferation and angiogenesis. 
In mice xenografts, tumor growth is inhibited  [114] ; how-
ever, complete regression has not been achieved  [113, 114, 
120] .
 Unfortunately, in patients, a recent, randomized, pla-
cebo-controlled, second-line phase III trial of sorafenib 
in combination with carboplatin and paclitaxel failed to 
prove beneficial in terms of overall or progression-free 
survival in patients with metastatic melanoma. However, 
the BRAF mutation status of the patient population in the 
trial was not assessed  [121] .
 More Specific BRAF Inhibitors 
 More specific inhibitors of mutated BRAF are current-
ly being investigated in clinical trials and have shown 
more promising results:
 – SB590885 (GlaxoSmithKline, Collegeville, Pa., USA) is 
a selective RAF inhibitor that preferentially targets 
mutated BRAF rather than wild-type BRAF and CRAF, 
thus leading to a decreased proliferation of tumor cells. 
BRAF V600 E mutated cells are inhibited 100-fold 
more potently by SB590885 than by sorafenib  [122] . 
 – RAF-265 (Chir 265; Novartis, Basel, Switzerland) se-
lectively inhibits BRAF, CRAF, and VEGFR 2 and 
leads to tumor regression in melanoma xenografts. 
Notably, downregulation of the MAPK pathway has 
only been obtained in RAS and BRAF mutated mela-
noma xenograft models  [123] . This agent is currently 
under clinical investigation (http://clinicaltrials.gov/
ct2/show/NCT00304525). On the other hand, the se-
lective V600E BRAF inhibitor PLX-4032 and its coun-
terpart PLX-4720 (Plexxikon, Berkeley, Calif., USA) 
have already shown inhibition of tumor growth pre-
clinically in BRAF V600E mutated cells but not in 
wild-type cells  [124, 125] . In a clinical phase I trial, a 
reduction of phosphorylated ERK was observed in 3 of 
6 patients with V600E BRAF-mutated metastatic mel-
anoma upon treatment with PLX4032  [126] . Further-
more, tumor regression was observed in 5 of 7 patients 
harboring the V600E BRAF mutation  [127] . 
 MEK Inhibitors 
 – PD0325901 (Pfizer, USA) showed responses in 3 out of 
22 melanoma patients in a clinical phase I trial; nota-
bly, 2 of them had BRAF mutations and 1 had an NRAS 
mutation. However, phase II trials were suspended due 
to cases of retinal vein thrombosis  [110, 128] .
 – AZD6244 (ARRY-142886; AstraZeneca, Wilmington, 
Del., USA), an inhibitor of MEK, induced G1-phase 
cell cycle arrest, decreased phosphorylated ERK, and 
showed high cytostatic activity in melanoma xeno-
grafts  [124, 129, 130] . Despite the xenograft tumor 
growth was suppressed, the cells remained viable 
 indicating that MEK inhibition alone is not sufficient 
to induce apoptosis. Tumor regression was achieved, 
however, using a combination of AZD6244 and 
docetaxel in melanoma xenografts  [129] . A random-
ized phase II trial of AZD6244 compared to temozolo-
mide reported partial responses in 6 out of 104 pa-
tients, 5 of which carried the BRAF mutation (12%) 
 [131] . Clinical trials restricted to patients carrying the 
BRAF mutation are ongoing.
 – NRAS inhibitors, specifically farnesyl transferase in-
hibitors, i.e. tipifarnib (Zarnestra  , R115777; Johnson 
& Johnson Pharmaceutical Research and Develop-
ment; Raritan, N.J., USA) and lonafarnib (Sarasar  , 
SCH 66336; Schering-Plough Corp., Kenliworth, N.J., 
USA), showed disappointing results in clinical phase 
III trials when applied as a monotherapy. Consequent-
ly, clinical trials using these inhibitors in combination 
with chemotherapy are ongoing  [110, 132] .
 At present, it is recommended that targeted therapy be 
combined with other therapeutic agents in the treatment 
of metastatic melanoma. In vitro and in vivo studies have 
shown that monotherapy with one targeted therapeutic 
agent may lead to tumor stabilization but not to regres-
sion  [129] . It is assumed that this is because of resistance 
attained through a switch from BRAF to CRAF signaling 
 [110] . This was demonstrated by one of the first studies of 
sorafenib, in which monotherapy showed disappointing 
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results: response in 1 out of 61 patients  [133] . However, 
patients benefitted from sorafenib therapy in combina-
tion with dacarbazine when compared to dacarbazine 
therapy alone  [134] .
 Targeted therapy seems to be a promising therapy op-
tion for patients with metastatic melanoma but further 
investigation is still required.
 c-KIT-Targeted Therapy 
 cKIT is located on chromosome 4q12 and codes for 
KIT, a tyrosine protein kinase receptor. It belongs to the 
class III tyrosine kinase receptor family  [135–138] . It 
spans a distance of about 80 kb, including 21 exons  [139] . 
In KIT-expressing melanocytes, KIT controls perma-
nent survival, proliferation, differentiation, and migra-
tion functions  [140] . Interestingly, the KIT gene origi-
nates from a gene duplication of an ancestral PDGFR 
(PDGF)/KIT locus, followed by a chromosomal duplica-
tion during the evolutionary mechanisms involved in the 
establishment of new cell populations such as neural 
crest-derived pigmented cells  [140] .
 Why KIT? 
 cKIT mutations are well known in gastrointestinal 
stroma tumors (GIST), chronic myeloid leukemia, germ 
line tumors such as testicular cancer, small cell lung can-
cer, and mastocytosis  [141] . Several reports of positive 
treatment results in GIST, stable phases of chronic my-
eloid leukemia, and acute myeloid leukemia  [142] prompt-
ed the idea to study other cancers’ KIT status  [143] . In 
GIST a high frequency of mutations in KIT was detected, 
leading to constitutive activation of the receptor  [144] . 
Went et al.  [145] were the first to detect activating cKIT 
mutations in melanoma.
 As it was found that acrolentiginous and mucosal mel-
anoma showed distinct chromosomal aberrations, sev-
eral studies focused on and identified cKIT mutations in 
these melanoma types in particular  [102, 103, 105, 106, 
146–150] . Targeting the KIT receptor using small-mole-
cule inhibitors such as imatinib showed successful results 
in certain GIST and was thus evaluated in vitro  [147–149, 
151]  as well as in vivo in clinical phase II studies for acro-
lentiginous and mucosal melanoma  [105, 150, 152–156] .
 Just recently, NRAS mutations were reported to occur 
more often in mucosal melanoma than KIT, which is a 
striking new finding  [151] .
 Imatinib in Melanoma – Successes and Problems 
 One of the first small molecules targeting KIT was the 
2-phenyl-aminopyrimidine, imatinib  [157–160] . It shows 
activity against several receptors such as bcr-abl, KIT, 
PDGF receptor (PDGFR)-  and PDGFR-  , ABL1, and 
ABL2 (ARG)  [157, 161] . Imatinib functions as a multiki-
nase competitive inhibitor, competing with ATP for the 
binding site of the tyrosine kinase domain of the KIT re-
ceptor. Imatinib can only bind to the nucleotide binding 
site within the juxtamembrane domain when the DFG 
(Asp 810 , Phe 811 , Gly 812 ) motif is present  [162, 163] .
 Imatinib has been tried in melanoma patients in sev-
eral clinical studies. The first clinical trial was performed 
by Ugurel et al.  [152] in 2005. Unfortunately, no sub-
grouping of melanoma took place, nor was the mutation 
status of KIT considered in a large group. In the 4 cell 
cultures studied, no mutations were found. Toxicity was 
outstandingly high in that study. These problems were 
also present in the study performed by Wyman et al.  [154] 
in 2006; no distinction between melanoma subtypes and 
neither immunohistochemical nor mutation analysis was 
performed before running the study. Coincidentally, 1 
patient suffered from mucosal melanoma, but no activat-
ing mutations were detected. Imatinib treatment was 
thus insufficient.
 Of the 31 patients studied by Kim et al.  [153] , 1 patient 
suffered from acrolentiginous melanoma, showing high 
KIT expression. Imatinib treatment led to a complete re-
sponse lasting up to 1 year. RNA sequencing revealed a 
deletion at codon 715 (kinase domain), a splice variant, 
which was not specific though. Biopsies were taken twice, 
i.e. before and during treatment. The 1 responding pa-
tient showed no alterations in KIT expression during 
treatment, while the nonresponding patients showed ei-
ther a reduction, an increase, or no change in KIT expres-
sion. Staining was not predictive of therapeutic response 
 [153] .
 In a clinical phase II study, Heinrich et al.  [164] ex-
plored the efficacy of imatinib in the treatment of several 
life-threatening malignancies. Seven melanoma patients 
were treated, but no effect of imatinib was observed. In 
2009, sunitinib showed promising effects in acral and 
mucosal melanoma in vitro  [150] .
 PDGFR-Targeted Therapy in DFSP  
 Dermatofibrosarcoma Protuberans 
 Dermatofibrosarcoma protuberans (DFSP) is the most 
common sarcoma evolving on the skin; however, it
is quite a rare disease with an incidence of less than 
1/100,000 per year  [165] . DFSPs in most cases are local-
ized on the body trunk (in 40–70%) in particular at the 
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presternal region and less frequently on the extremities 
and head and neck area [166]. Clinically DFSP presents in 
different forms, often as a plaque on which nodules can 
evolve. Besides the classical dermatofibroblastic tumor, 
the fibrosarcomatous variant, FS-DFSP, is seen as its pro-
gressive form with increased metastatic potential. The 
pigmented DFSP, or so called Bednar-tumor, is another 
subtype which is histologically defined by the occurrence 
of melanin-containing dendritic cells. Pigmented DFSP, 
as well as DFSP in general, was reported to be more fre-
quent in the Afro-American population [166, 167]. Spe-
cific juvenile form of DFSP is called giant cell fibroblas-
toma (GCF) where chromosomal alterations are often 
found [168]. All variants show staining-positivity for 
CD34 [169] and histological evaluation is always required 
to make a definitive diagnosis of DFSP [170]. Magnetic 
resonance imaging (MRI) is helpful for estimation of the 
tumor’s extent  [171, 172] . So far, the only staging system 
that exists was introduced by Ugurel et al.  [173] , accord-
ing to the Short German Guidelines for DFSP, suggesting 
the following: stage I, primary tumor; stage II, including 
lymph node metastases, and stage III, with distant metas-
tases.
 Clinical Development and Presentation 
 Accretion and development of DFSP takes place over 
a long time, occasionally years, and diagnosis is often 
made when the tumor has already progressed and spread. 
Local infiltration is characterized by asymmetric and 
horizontal branches, often a few centimeters long, 
 sometimes infiltrating subcutaneous structures such as 
fascia, muscles, or even bones. Clinically, DFSP can 
 present as skin-colored, brown-to-yellowish, red-tinged, 
sclerodermiform, or telangiectatic skin  [171] . Misdiagno-
sis as benign skin lesions, such as dermatofibroma and 
nevi, among others, is another reason for the often late 
diagnosis. A typical character trait includes the indura-
tion and compact consistency of lesions.
 Most patients are under 40 years of age. Special risk 
factors are not known; however, an increased age ( 1 50 
years) is associated with a higher propensity for recur-
rence  [174] .
 Current Therapy Options 
 Surgery in the early stage is currently the therapy of 
choice. A challenge is the safety margin (according to the 
literature it is between 1 and 5 cm), especially in regions 
such as the presternal or head-neck area where healing 
with widespread scarring can often be observed. Immu-
nohistochemical staining with CD34 is recommended in 
order to evaluate the tumor borders in the excised por-
tion. Mohs micrographic surgery allows optimal tumor 
excision while minimizing the excision of healthy tissue, 
thus resulting in less complicated wound healing  [170, 
175, 176] .
 DFSP is regarded as radiosensitive; thus, postopera-
tive adjuvant radiotherapy is suggested to reduce the risk 
of local recurrences, especially in patients with narrow 
and/or positive surgical margins  [177–180] . No remark-
able benefits are known for conventional chemotherapy 
 [165] .
 New Molecular Background and Treatment Options 
 Once the tumor has spread, systemic therapy is re-
quired. It has been shown that PDGFR plays a crucial role 
in the pathogenesis of DFSP. PDGFR is of importance for 
biological effects such as angiogenesis, cell proliferation, 
and apoptosis  [181] .
 A translocation of t(17; 22) takes place in over 90% of 
all DSFP patients  [182] . The collagen type 1 alpha 1 gene 
(COLIA1) encoding type I collagen (chromosome 17) and 
PDGFR (chromosome 22) are located within chromo-
somal regions affected by this translocation. Fusion of 
these chromosomes in DFSP leads to constitutively over-
expressed PDGFR, causing a continuous autocrine stim-
ulation of tumor cell proliferation. Simultaneously, natu-
ral apoptosis is inhibited due to the permanent stimula-
tion of the signal transduction pathway. Already in 1999 
Shimizu et al.  [183] found a relevant correlation between 
COLIA1-PDGF-b gene fusion and the inhibition of tu-
mor growth by applying CGP57148B, a PDGF-b inhibi-
tor, in vitro. Interestingly, Shimizu et al.  [183] suggested 
that the COLIA1 part did not contribute to the cellular 
phenotype. However, the suggested fibroblastic origin of 
the tumor is attributed to the COLIA1 part  [184] . Sjöblom 
et al.  [185] showed STI571-induced (imanitib/Glivec  ) 
apoptosis of DFSP tumor cells but no antiangiogenic ef-
fects in in vitro experiments. However, the vascular mor-
phology was reported to be altered upon STI571 treat-
ment.
 Who Benefits from Targeting PDGFR? 
 DFSP is the first dermatological tumor for which sig-
nal transduction therapy was approved based on a study 
of 25 cases of locally spread, recurrent or metastatic DFSP 
that responded successfully to imatinib  [152, 186] . Ima-
tinib is a small multikinase inhibitor targeting PDGFR 
among other vital kinase receptors such as KIT. The first 
patient treated with imatinib showed impressive remis-
sion of the tumor, which had already metastasized  [187] . 
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McArthur and et al.  [186] showed that out of 10 patients 
with locally advanced or metastatic disease the only one 
without positivity for the t(17; 22) translocation did not 
respond to imatinib; it was thus concluded that the fusion 
protein is crucial for therapeutic benefit  [164] . Interest-
ingly, in contrast to imatinib treatment in GIST, neither 
high levels of receptor tyrosine kinase activation nor 
overexpression of the protein was required for successful 
small-molecule inhibition  [186] .
 In 2005, Price et al.  [188] administered imatinib to a 
child with DFSP, achieving successful tumor treatment. 
Labropoulos et al.  [189] treated a patient with locally ad-
vanced recurrent fibrosarcomatous DFSP who had al-
ready developed metastases. Imatinib treatment (400 mg 
daily) led to a complete response  [189] .
 Effects of Imatinib 
 If imatinib serves as a preoperative treatment option 
to reduce tumors to a reasonable size, 4–8 weeks after the 
start of treatment a relevant tumor growth reduction 
should be seen on MRI. Tumor cells are transformed into 
less viable hyaline fibers and thus lose vitality  [186, 190] . 
The reduction of vital cells allows a smaller safety margin 
for the surgical treatment thereof. If no response can be 
detected at that time, a therapeutic failure is to be consid-
ered. Clinical studies for adjuvant imatinib treatment, es-
pecially after repeated local recurrences, are still to be 
performed.
 The development of imatinib resistance is challenging; 
so far, no methods for predicting or preventing this are 
known  [186] . To avoid resistance, other inhibitors such
as sunitinib, dasatinib, and nilotinib should be evaluated 
in clinical trials on DFSP patients.
 Conclusion 
 Imatinib has been shown to target PDGFR in particu-
lar, blocking tumor growth and proliferation in DFSP. 
The striking success of imatinib in DFSP and in cKIT-
mutated mucosal or acrolentiginous melanoma is an ex-
ample for the potential of targeted therapy in skin cancers 
on one side. On the other side, melanoma perfectly re-
flects the complexity of pathways resulting in a highly ag-
gressive malignancy. Targeted therapy has recently also 
yielded antitumor effects in melanoma patients with mu-
tations in the BRAF. Despite several new promising small 
molecules there are still no therapeutic strategies that reli-
ably increase the survival of patients with advanced dis-
ease. Large therapeutic trials including genomic and tran-
scriptional analysis shall identify the subpopulations of 
skin cancer patients that may profit from the molecules 
available today. With regard to BCC and SCC the conclu-
sions are similar. Hopefully, intensive basic research to-
gether with translational research in the context of well-
designed clinical trials will pave the way to a successful 
and well-tolerated personalized medical management.
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